These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2947053)

  • 1. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.
    Mathé G; Schally AV; Comaru-Schally AM; Mauvernay RY; Vovan ML; Machover D; Misset JL; Court B; Bouchard P; Duchier J
    Prostate; 1986; 9(4):327-42. PubMed ID: 2947053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
    Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
    Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Ureta-Sanchez S; Berea Dominguez H; Graef-Sanchez A; Becerril Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1985; 7(1):21-30. PubMed ID: 2934692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
    Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
    Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW; Schally AV
    Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advanced cancer of the prostate. Treatment with an LH-RH agonist, D-Trp-6-LH-RH].
    Mathé G; Misset JL; Vovan ML; Machover D
    Bull Cancer; 1986; 73(1):31-5. PubMed ID: 2430652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Berea-Dominguez H; Graef-Sanchez A; Becerril-Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1986; 9(2):207-15. PubMed ID: 2944084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oriented phase-II trial of D-Trp6-LH-RH in patients with prostatic carcinoma.
    Mathé G; Vo Van ML; Duchier J; Misset JL; Morin P; Keiling R; Schwarzenberg L; Kerbrat P; Achille E; Tronc JC
    Med Oncol Tumor Pharmacother; 1984; 1(2):119-22. PubMed ID: 6242478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contribution to studies on the treatment of cancer of the prostate with D-Trp6-LH-RH].
    Marcellino LR; Campanella A; Bandini M
    Biomed Pharmacother; 1987; 41(9-10):468-72. PubMed ID: 2968123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of prostatic cancers by periodic administration of a delayed-release preparation of D-Trp(6)-LHRH].
    Roger M; Duchier J; Lahlou N; Schally AV
    Ann Urol (Paris); 1986; 20(2):109-12. PubMed ID: 2424359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
    Zalatnai A; Paz-Bouza JI; Redding TW; Schally AV
    Prostate; 1988; 12(1):85-98. PubMed ID: 2894651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A; Germinale T
    Am J Clin Oncol; 1988; 11 Suppl 2():S129-31. PubMed ID: 2977269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Decapeptyl (D-Trp6-LH-RH) in the therapy of prostatic cancer with reference to the intramuscular administration of a depot preparation].
    Seppelt U; Bertermann H; Saerbeck C
    Urologe A; 1986 Sep; 25(5):298-301. PubMed ID: 2947371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of advanced prostatic cancer with a gonadorelin agonist, dTrp6 LHRH. 41 cases].
    Steg A; Chiche R; Boccon-Gibod L; Debré B
    Presse Med; 1985 Nov; 14(40):2045-8. PubMed ID: 2934695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.